Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
AGITG DOCTOR试验的患者报告结局(PRO)结果:一项针对可切除食管腺癌的个体化新辅助治疗的随机II期试验
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-09270-4
Mercieca-Bebber, R; Barnes, E H; Wilson, K; Samoon, Z; Walpole, E; Mai, T; Ackland, S; Burge, M; Dickie, G; Watson, D; Leung, J; Wang, T; Bohmer, R; Cameron, D; Simes, J; Gebski, V; Smithers, M; Thomas, J; Zalcberg, J; Barbour, A P